Showing results (61-70 of 172) with videos related to

Sort By:
Pageof 18
ESMO Open|September 19, 2020
Retrospective analysis of the prevalence of specialised palliative care services for patients with metastatic breast cancerEva Maria Jäger, Martin Filipits, Anna Glechner, et al.
Annals of Hematology|January 24, 2018
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myelomaIris Breitkreutz, Klaus Podar, Vianihuini Figueroa-Vazquez, et al.
Plos One|March 3, 2016
Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET PathwaySonia Vallet, Muhammad Hasan Bashari, Feng-Juan Fan, et al.
Anticancer Research|August 17, 2005
Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patientsNiklas Zojer, Karin Brenner, Dora Beke, et al.
Oncogene|September 19, 2003
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cellsDharminder Chauhan, Guilan Li, Martin Sattler, et al.
Cancer Letters|January 26, 2025
Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemiaStefanie Weiss, Bernhard Zdársky, Agnieszka Witalisz-Siepracka, et al.
The Journal of Biological Chemistry|April 1, 2003
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cellsDharminder Chauhan, Guilan Li, Teru Hideshima, et al.
Molecular Cancer Therapeutics|December 14, 2002
The biological sequelae of stromal cell-derived factor-1alpha in multiple myelomaTeru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, et al.
Blood|November 17, 2007
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myelomaDharminder Chauhan, Ajita Singh, Mohan Brahmandam, et al.
Oncogene|April 20, 2004
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341Dharminder Chauhan, Guilan Li, Teru Hideshima, et al.
Pageof 18